Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy
Sponsor study identifier
interventional
32
1 country
1
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2007
Actual (reported)Study Completion
June 2007
Actual (reported)The purpose of this study is to measure the therapeutic potential of Escherichia coli (E. coli) and yeast ribosomal Ribonucleic acid (RNA) fragments to maintain the production of platelets in patients undergoing cytotoxic therapy for cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
June 2007
Actual (reported)June 2007
Actual (reported)July 13, 2010
Actual (reported)July 15, 2010
Actual (reported)Determine whether E. coli or yeast ribosomal ribonucleic acid (rRNA) fragments prophylactically prevent the development of thrombocytopenia during chemotherapy.
Time to Platelet recovery after nadir
Determine whether E. coli or yeast rRNA fragments accelerate the recovery of platelets in patients undergoing chemotherapy.
Time to platelet transfusion 3 weeks after nadir
Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Midwestern Regional Medical Center
Zion, Illinois, 60099, United States
Levin RD, Daehler M, Grutsch JF, Hall JL, Gupta D, Lis CG. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC Cancer. 2010 Oct 19;10:565. doi: 10.1186/1471-2407-10-565.
Robert Levin, MD
Midwestern Regional Medical Center
32 participants (actual enrollment reported by the registry).
First Submitted
July 13, 2010
First Posted
July 15, 2010
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Contact the study team to confirm eligibility.
Primary Completion
June 2007
Actual (reported)Study Completion
June 2007
Actual (reported)Last Updated
November 15, 2013
Record last verified: 2013-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: